# Phase 2 Closeout Evidence

Recorded: 2026-08-13

Phase status: **COMPLETE / FOUNDER_APPROVED**

## Acceptance conclusion

Phase 2's objective—hardened authentication identity propagation, safe authorization defaults, and verified organization/location tenant isolation—is satisfied. The founder approved Phase 2 after its authoritative verification and independent review passed.

## Verification and review evidence

- The authoritative Phase 2 run is [`runs/2026-08-13T23-59-52-802Z`](./runs/2026-08-13T23-59-52-802Z/).
- The run records `verificationState: "PASS"` and `phaseStatus: "READY_FOR_FOUNDER_REVIEW"`.
- Typecheck, unit tests, and build passed.
- Lint reproduced only the exact approved Phase 4 debt and was classified `COMPLETE_WITH_KNOWN_DEBT`.
- Integration reproduced only the exact approved Phase 3 visit-discharge mismatch and was classified `COMPLETE_WITH_KNOWN_DEBT`.
- Playwright reproduced the exact approved identity-based baseline of 24 failed, 1 did not run, and 5 passed, and was classified `COMPLETE_WITH_KNOWN_DEBT`.
- Claude Review 1 is recorded as **PASS** in [`review-1.md`](./runs/2026-08-13T23-59-52-802Z/review-1.md) and [`review-1.json`](./runs/2026-08-13T23-59-52-802Z/review-1.json).

## Preserved artifacts

All Phase 2 planning, implementation, remediation, verification, review, and run-state artifacts remain unchanged. This closeout records the founder decision in durable project memory without rewriting historical run state or rerunning verification.

## Deferred findings

- Claude Review 1's low-severity, non-blocking development-fixture hygiene finding remains recorded in the review artifact; it did not block the review pass or founder approval.
- The exact visit-discharge behavior/assertion mismatch is now active Phase 3 scope.
- The approved Phase 4 inventory lint and `@ts-nocheck` debt remains deferred.
- Historical Playwright product/test drift remains assigned to the appropriate later product phases; it was not remediated by this closeout.

## Handoff

Phase 2 is complete and founder-approved. Phase 3 — Clinical Workflow Integrity is the next approved and active phase. No Phase 3 implementation, execution, or verification is part of this closeout.
